+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Chemotherapy-Induced Anemia

  • ID: 4846160
  • Report
  • February 2020
  • Region: Global
  • 32 pages
  • Datamonitor Healthcare
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen
  • Johnson & Johnson
  • MORE
This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The proportions of CIA and the severity of anemia vary by region, cancer type, and stage.

All of the approved drugs for CIA target the erythropoietin receptor. These drugs are all administered via both the intravenous and subcutaneous routes.

There are only two industry-sponsored drugs in active clinical development for CIA, both of which are in Phase III. Therapies in development for CIA focus on targets such as iron and hypoxia-inducible factor-prolyl hydroxylase. These drugs are administered via the intravenous and oral routes.

The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 24.3%, and the average probability a drug advances from Phase III is 81.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.1 years in the overall hematology space.

There have been only two licensing and asset acquisition deals involving CIA drugs during 2015–20. The values of the deals have not been disclosed.

The distribution of clinical trials across Phase I–IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III–IV, and 39% in Phase I–II.

Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 67 trials.
Amgen leads industry sponsors with the highest number of clinical trials for CIA, followed by Johnson & Johnson.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen
  • Johnson & Johnson
  • MORE
1. OVERVIEW

2. KEY TAKEAWAYS

3. DISEASE BACKGROUND
  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis
4. TREATMENT
  • Iron supplements
  • Blood transfusion
  • Erythropoietin-stimulating agents (ESAs)
5. EPIDEMIOLOGY

6. MARKETED DRUGS

7. PIPELINE DRUGS

8. RECENT EVENTS AND ANALYST OPINION
  • Roxadustat for CIA (December 9, 2019)
9. PROBABILITY OF SUCCESS

10. LICENSING AND ASSET ACQUISITION DEALS

11. PARENT PATENTS

12. REVENUE OPPORTUNITY

13. CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
14. BIBLIOGRAPHY
  • Prescription information
15. APPENDIX

LIST OF FIGURES
Figure 1: Overview of pipeline drugs for CIA in the US
Figure 2: Pipeline drugs for CIA, by company
Figure 3: Pipeline drugs for CIA, by drug type
Figure 4: Pipeline drugs for CIA, by classification
Figure 5: Roxadustat for CIA (December 9, 2019): Phase III - MDS (US)
Figure 6: Probability of success in the CIA pipeline
Figure 7: Licensing and asset acquisition deals in CIA, 2015–20
Figure 8: Clinical trials in CIA
Figure 9: Top 10 drugs for clinical trials in CIA
Figure 10: Top 10 companies for clinical trials in CIA
Figure 11: CIA trials status
Figure 12: CIA trials sponsors, by phase

LIST OF TABLES
Table 1: Chemotherapy-treated patients with CIA, by grade, in the US
Table 2: Marketed drugs for CIA
Table 3: Pipeline drugs for CIA in the US
Table 4: Roxadustat for CIA (December 9, 2019)
Table 5: Parent patents in CIA
Table 6: Historical global sales, by drug ($m), 2014–18
Table 7: Forecasted global sales, by drug ($m), 2020–24
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Amgen
  • Johnson & Johnson
Note: Product cover images may vary from those shown
Adroll
adroll